Advaxis Inc. stock has taken a battering following the news that the FDA has placed a clinical hold on a Phase I/II trial of axalimogene filolisbac in combination with AstraZeneca PLC's PD-L1 inhibitor Imfinzi (durvalumab) to treat human papillomavirus (HPV)-related cancers after a patient death, although the US biotech does not believe its drug was the cause.
Shares in Advaxis fell 22% to $1.72 in after-hours trading March 12 after the company revealed that it received notification of the hold from the FDA on the evening of March 9